CONTEXT: Dimethandrolone undecanoate (DMAU) is being developed as a male contraceptive. Daily oral administration of DMAU, a potent androgen that is not aromatized, markedly suppresses serum testosterone (T) and estradiol (E2) in healthy men. E2 deficiency can increase bone resorption in men. OBJECTIVE: This work aimed to assess changes in bone turnover markers with DMAU administration in a 28-day study. DESIGN: A randomized, double-blind, placebo-controlled study was conducted. SETTING: This study took place at 2 academic medical centers. PARTICIPANTS: Healthy men, age 18 to50 years (n = 81), participated. INTERVENTION: Men received 0, 100, 200, or 400 mg of oral DMAU for 28 days. Serum C-terminal telopeptide of type I collagen (CTX; bone resorption marker) and procollagen type I amino-terminal propeptide (P1NP; bone formation marker) were measured on days 1 and 28. MAIN OUTCOME MEASURES: Changes in bone turnover markers and serum hormones over the treatment period were measured. RESULTS: On day 28, median serum T and E2 were markedly suppressed in all treatment groups vs placebo (P < .001 for both). Percentage change (%) in serum P1NP significantly differed across treatment groups (P = .007): Serum P1NP significantly increased in the 200 mg (5%, interquartile range [IQR] -7% to 27%) and 400 mg (22%, IQR -1% to 40%) groups relative to placebo (-8%, IQR -20% to 0%). Change (%) in serum CTX did not differ between groups (P = .09). CONCLUSIONS: DMAU administration for 28 days to healthy men leads to marked suppression of serum T and E2, yet increases P1NP, a serum marker of bone formation. Longer-term studies of the potent androgen DMAU are warranted to determine its impact on bone health in men.
CONTEXT: Dimethandrolone undecanoate (DMAU) is being developed as a male contraceptive. Daily oral administration of DMAU, a potent androgen that is not aromatized, markedly suppresses serum testosterone (T) and estradiol (E2) in healthy men. E2 deficiency can increase bone resorption in men. OBJECTIVE: This work aimed to assess changes in bone turnover markers with DMAU administration in a 28-day study. DESIGN: A randomized, double-blind, placebo-controlled study was conducted. SETTING: This study took place at 2 academic medical centers. PARTICIPANTS: Healthy men, age 18 to50 years (n = 81), participated. INTERVENTION: Men received 0, 100, 200, or 400 mg of oral DMAU for 28 days. Serum C-terminal telopeptide of type I collagen (CTX; bone resorption marker) and procollagen type I amino-terminal propeptide (P1NP; bone formation marker) were measured on days 1 and 28. MAIN OUTCOME MEASURES: Changes in bone turnover markers and serum hormones over the treatment period were measured. RESULTS: On day 28, median serum T and E2 were markedly suppressed in all treatment groups vs placebo (P < .001 for both). Percentage change (%) in serum P1NP significantly differed across treatment groups (P = .007): Serum P1NP significantly increased in the 200 mg (5%, interquartile range [IQR] -7% to 27%) and 400 mg (22%, IQR -1% to 40%) groups relative to placebo (-8%, IQR -20% to 0%). Change (%) in serum CTX did not differ between groups (P = .09). CONCLUSIONS: DMAU administration for 28 days to healthy men leads to marked suppression of serum T and E2, yet increases P1NP, a serum marker of bone formation. Longer-term studies of the potent androgen DMAU are warranted to determine its impact on bone health in men.
Authors: C Wang; D R Eyre; R Clark; D Kleinberg; C Newman; A Iranmanesh; J Veldhuis; R E Dudley; N Berman; T Davidson; T J Barstow; R Sinow; G Alexander; R S Swerdloff Journal: J Clin Endocrinol Metab Date: 1996-10 Impact factor: 5.958
Authors: Andrea Di Nisio; Luca De Toni; Elena Speltra; Maria Santa Rocca; Giuseppe Taglialavoro; Alberto Ferlin; Carlo Foresta Journal: Endocrinology Date: 2015-09-22 Impact factor: 4.736
Authors: Ammar Qoubaitary; Cristina Meriggiola; Chiu Ming Ng; Leslie Lumbreras; Silvia Cerpolini; G Pelusi; Peter D Christensen; Laura Hull; Ronald S Swerdloff; Christina Wang Journal: J Androl Date: 2006-07-12
Authors: S A Paul Chubb; Elizabeth Byrnes; Laurens Manning; John P Beilby; Peter R Ebeling; Samuel D Vasikaran; Jonathan Golledge; Leon Flicker; Bu B Yeap Journal: J Clin Endocrinol Metab Date: 2015-01 Impact factor: 5.958
Authors: Dan Mellström; Liesbeth Vandenput; Hans Mallmin; Anna H Holmberg; Mattias Lorentzon; Anders Odén; Helena Johansson; Eric S Orwoll; Fernand Labrie; Magnus K Karlsson; Osten Ljunggren; Claes Ohlsson Journal: J Bone Miner Res Date: 2008-10 Impact factor: 6.741
Authors: Barbara J Attardi; Trung C Pham; Lisa C Radler; Janet Burgenson; Sheri A Hild; Jerry R Reel Journal: J Steroid Biochem Mol Biol Date: 2008-06 Impact factor: 4.292